Abstract
Human immunodeficiency virus type 1 (HIV-1) requires a chemokine receptor (CCR5 or CXCR4) as a coreceptor not only for initiate viral entry but also protecting highly conserved neutralization epitopes from the attack of neutralizing antibodies. Over the past decade, many studies have provided new insights into the HIV entry mechanism and have focused on developing an effective vaccine strategy. However, to date, no vaccine that can provide protection from HIV-1 infection has been developed. One reason for the disappointing results has been the inability of current vaccine candidates to elicit a broadly reactive immunity to viral proteins such as the envelope (env) protein. Here, we propose that chemokine receptors are attractive targets of vaccine development because their structures are highly conserved and that our synthetic cycloimmunogens can mimic conformational-specific epitopes of undecapeptidyl arches (UPAs: R168-C178 in CCR5, N176-C186 in CXCR4) and be useful for HIV-1 novel vaccine development.
Keywords: Cycloimmunogen, HIV-1, conformational epitope, CCR5, CXCR4
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Immunoreactive Cycloimmunogen Design Based on Conformational Epitopes Derived from Human Immunodeficiency Virus Type 1 Coreceptors:Cyclic Dodecapeptides Mimic Undecapeptidyl Arches of Extracellular Loop-2 in Chemokine Receptor and Inhibit Human Immunodeficiency Virus Type 1 Infection
Volume: 7 Issue: 2
Author(s): Shogo Misumi, Nobutoki Takamune and Shozo Shoji
Affiliation:
Keywords: Cycloimmunogen, HIV-1, conformational epitope, CCR5, CXCR4
Abstract: Human immunodeficiency virus type 1 (HIV-1) requires a chemokine receptor (CCR5 or CXCR4) as a coreceptor not only for initiate viral entry but also protecting highly conserved neutralization epitopes from the attack of neutralizing antibodies. Over the past decade, many studies have provided new insights into the HIV entry mechanism and have focused on developing an effective vaccine strategy. However, to date, no vaccine that can provide protection from HIV-1 infection has been developed. One reason for the disappointing results has been the inability of current vaccine candidates to elicit a broadly reactive immunity to viral proteins such as the envelope (env) protein. Here, we propose that chemokine receptors are attractive targets of vaccine development because their structures are highly conserved and that our synthetic cycloimmunogens can mimic conformational-specific epitopes of undecapeptidyl arches (UPAs: R168-C178 in CCR5, N176-C186 in CXCR4) and be useful for HIV-1 novel vaccine development.
Export Options
About this article
Cite this article as:
Misumi Shogo, Takamune Nobutoki and Shoji Shozo, Immunoreactive Cycloimmunogen Design Based on Conformational Epitopes Derived from Human Immunodeficiency Virus Type 1 Coreceptors:Cyclic Dodecapeptides Mimic Undecapeptidyl Arches of Extracellular Loop-2 in Chemokine Receptor and Inhibit Human Immunodeficiency Virus Type 1 Infection, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187153007780832127
DOI https://dx.doi.org/10.2174/187153007780832127 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect on the Intestine of Some Fungal Toxins: The Trichothecenes
Current Immunology Reviews (Discontinued) Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Chitosan and Its Use in Design of Insulin Delivery System
Recent Patents on Drug Delivery & Formulation Chelating Agents for the Treatment of Systemic Iron Overload
Current Medicinal Chemistry Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Experience with Androgen Deprivation Therapy for Prostate Cancer in Japan and Future Perspectives
Current Cancer Drug Targets Getting an Insight into the Complexity of Major Chronic Inflammatory and Degenerative Diseases: A Potential New Systemic Approach to Their Treatment
Current Pharmaceutical Biotechnology Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Hypothalamic Glucose Sensing and Glycaemic Disease
Current Diabetes Reviews Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety The Antibiotic Effects of Vitamin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemotherapy for Prostate Cancer
Current Pharmaceutical Design